+
Open data
-
Basic information
Entry | ![]() | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Title | Structure of URAT1 in complex with TD-3 | |||||||||
![]() | full map | |||||||||
![]() |
| |||||||||
![]() | Membrane protein / membrane transporter / TRANSPORT PROTEIN | |||||||||
Biological species | ![]() | |||||||||
Method | single particle reconstruction / cryo EM / Resolution: 2.55 Å | |||||||||
![]() | Suo Y / Fedor JG / Lee S-Y | |||||||||
Funding support | ![]()
| |||||||||
![]() | ![]() Title: Molecular basis of the urate transporter URAT1 inhibition by gout drugs. Authors: Yang Suo / Justin G Fedor / Han Zhang / Kalina Tsolova / Xiaoyu Shi / Kedar Sharma / Shweta Kumari / Mario Borgnia / Peng Zhan / Wonpil Im / Seok-Yong Lee / ![]() ![]() Abstract: Hyperuricemia is a condition when uric acid, a waste product of purine metabolism, accumulates in the blood. Untreated hyperuricemia can lead to crystal formation of monosodium urate in the joints, ...Hyperuricemia is a condition when uric acid, a waste product of purine metabolism, accumulates in the blood. Untreated hyperuricemia can lead to crystal formation of monosodium urate in the joints, causing a painful inflammatory disease known as gout. These conditions are associated with many other diseases and affect a significant and increasing proportion of the population. The human urate transporter 1 (URAT1) is responsible for the reabsorption of ~90% of uric acid in the kidneys back into the blood, making it a primary target for treating hyperuricemia and gout. Despite decades of research and development, clinically available URAT1 inhibitors have limitations because the molecular basis of URAT1 inhibition by gout drugs remains unknown. Here we present cryo-electron microscopy structures of URAT1 alone and in complex with three clinically relevant inhibitors: benzbromarone, lesinurad, and the recently developed compound TD-3. Together with functional experiments and molecular dynamics simulations, we reveal that these inhibitors bind selectively to URAT1 in inward-open states. Furthermore, we discover differences in the inhibitor-dependent URAT1 conformations as well as interaction networks, which contribute to drug specificity. Our findings illuminate a general theme for URAT1 inhibition, paving the way for the design of next-generation URAT1 inhibitors in the treatment of gout and hyperuricemia. | |||||||||
History |
|
-
Structure visualization
Supplemental images |
---|
-
Downloads & links
-EMDB archive
Map data | ![]() | 59.8 MB | ![]() | |
---|---|---|---|---|
Header (meta data) | ![]() ![]() | 19.6 KB 19.6 KB | Display Display | ![]() |
Images | ![]() | 89.9 KB | ||
Filedesc metadata | ![]() | 6.6 KB | ||
Others | ![]() ![]() | 59.5 MB 59.5 MB | ||
Archive directory | ![]() ![]() | HTTPS FTP |
-Related structure data
Related structure data | ![]() 9dkcMC ![]() 9dk9C ![]() 9dkaC ![]() 9dkbC M: atomic model generated by this map C: citing same article ( |
---|
-
Links
EMDB pages | ![]() ![]() |
---|
-
Map
File | ![]() | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | full map | ||||||||||||||||||||||||||||||||||||
Projections & slices | Image control
Images are generated by Spider. | ||||||||||||||||||||||||||||||||||||
Voxel size | X=Y=Z: 0.8469 Å | ||||||||||||||||||||||||||||||||||||
Density |
| ||||||||||||||||||||||||||||||||||||
Symmetry | Space group: 1 | ||||||||||||||||||||||||||||||||||||
Details | EMDB XML:
|
-Supplemental data
-Half map: half map 1
File | emd_46951_half_map_1.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | half map 1 | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-Half map: half map 2
File | emd_46951_half_map_2.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | half map 2 | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-
Sample components
-Entire : URAT1
Entire | Name: URAT1 |
---|---|
Components |
|
-Supramolecule #1: URAT1
Supramolecule | Name: URAT1 / type: complex / ID: 1 / Parent: 0 / Macromolecule list: #1 |
---|---|
Source (natural) | Organism: ![]() |
Molecular weight | Theoretical: 55 KDa |
-Macromolecule #1: URAT1
Macromolecule | Name: URAT1 / type: protein_or_peptide / ID: 1 / Number of copies: 1 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: ![]() |
Molecular weight | Theoretical: 55.379844 KDa |
Recombinant expression | Organism: ![]() |
Sequence | String: MAFSELLDQV GGLGRFQVLQ TVALVVPIMW LCTQSMLENF SAAVPSHRCW VPLLDNSTAQ ASVPGALGPE ALLAVSIPPG PNQGPHQCR RFRQPQWQLL DPNATATNWS EAATEPCVDG WVYDRSTFTS TIVAKWDLVC DSQALKPMAQ SIYLAGILVG A AVCGPASD ...String: MAFSELLDQV GGLGRFQVLQ TVALVVPIMW LCTQSMLENF SAAVPSHRCW VPLLDNSTAQ ASVPGALGPE ALLAVSIPPG PNQGPHQCR RFRQPQWQLL DPNATATNWS EAATEPCVDG WVYDRSTFTS TIVAKWDLVC DSQALKPMAQ SIYLAGILVG A AVCGPASD RFGRRLVLTW SYLQMAVSGT AAAFAPTFPV YCLFRFLVAF AVAGVMMNTG TLVMEWTSAQ ARPLVMTLNS LG FSFGHVL MAAVAYGVRD WALLQLVVSV PFFLCFVYSC WLAESARWLL ITGRLDRGLR ELQRVAAING KRAVGDTLTP QVL LSAMQE ELSVGQAPAS LGTLLRTPGL RLRTCISTLC WFAFGFTFFG LALDLQALGS NIFLLQVLIG VVDIPAKIGT LLLL SRLGR RPTQAASLVL AGLCILANTL VPHEMGALRS ALAVLGLGGL GAAFTCITIY SGELFPTVLR MTAVGLGQMA ARGGA ILGP LVRLLGVHGP WLPLLVYGTV PVLSGLAALL LPET |
-Macromolecule #2: 2-({1-[(4-bromonaphthalen-1-yl)methyl]-1H-imidazo[4,5-b]pyridin-2...
Macromolecule | Name: 2-({1-[(4-bromonaphthalen-1-yl)methyl]-1H-imidazo[4,5-b]pyridin-2-yl}sulfanyl)-2-methylpropanoic acid type: ligand / ID: 2 / Number of copies: 1 / Formula: A1A45 |
---|---|
Molecular weight | Theoretical: 456.356 Da |
-Experimental details
-Structure determination
Method | cryo EM |
---|---|
![]() | single particle reconstruction |
Aggregation state | particle |
-
Sample preparation
Concentration | 10 mg/mL | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Buffer | pH: 8 Component:
| ||||||||||||
Grid | Model: Quantifoil R1.2/1.3 / Support film - Material: GOLD / Support film - topology: HOLEY / Pretreatment - Type: GLOW DISCHARGE / Pretreatment - Time: 300 sec. / Pretreatment - Atmosphere: AIR / Pretreatment - Pressure: 0.00039000000000000005 kPa | ||||||||||||
Vitrification | Cryogen name: ETHANE / Chamber humidity: 95 % / Chamber temperature: 280 K / Instrument: LEICA EM GP | ||||||||||||
Details | Monodisperse sample |
-
Electron microscopy
Microscope | TFS KRIOS |
---|---|
Temperature | Max: 70.0 K |
Specialist optics | Energy filter - Name: GIF Bioquantum / Energy filter - Slit width: 20 eV |
Image recording | Film or detector model: GATAN K3 (6k x 4k) / Digitization - Dimensions - Width: 5760 pixel / Digitization - Dimensions - Height: 4092 pixel / Number grids imaged: 1 / Number real images: 18880 / Average exposure time: 1.8 sec. / Average electron dose: 50.0 e/Å2 |
Electron beam | Acceleration voltage: 300 kV / Electron source: ![]() |
Electron optics | C2 aperture diameter: 100.0 µm / Illumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD / Cs: 2.7 mm / Nominal defocus max: 2.0 µm / Nominal defocus min: 1.0 µm / Nominal magnification: 105000 |
Sample stage | Specimen holder model: FEI TITAN KRIOS AUTOGRID HOLDER / Cooling holder cryogen: NITROGEN |
Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |